Amid the COVID-19 pandemic, India appears for Oxford-AstraZeneca vaccine candidate are the likely first shot available for Indians at the end of 2020.

Additionally, there are two indigenously developed vaccine candidates, that are likewise being anticipated to have started with a gap few weeks if removed in trials, said a report from The Times of India citing officers.

On the other hand, the COVID-19 vaccine candidate produced at the University of Oxford is ahead of the other two local vaccine candidates that have entered the human clinical trials,'' the report said.

The SII, that has been allowed for conducting advanced phases of human clinical trials from the candidate from India, has started Phases two and three trials, stated the report.

<span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.bbc.com/news/world-australia-53826846">The locally designed vaccine candidates -- Bharat Biotech's Covaxin, jointly developed with the Indian Council of Medical Research (ICMR), also Zydus Cadila's Zycov D are equally in early phases of clinical trials, as per the report.</a></span>

The trials by SII are the largest, which is being conducted with around 1,600 people aged over 18 years in over 17 selected sites across the country, for the COVID-19 vaccine from the country up to now. For the trials of the other vaccine candidates, that there have been approximately 1,000-1,100 participants registered in five to eight sites, said that the report.

Also, in contrast of other offenses being developed beyond India, the Oxford vaccine candidate has scored much better as it has an Indian company -- SII -- as a production and distribution partner.

SII, that plans to make 100 million doses of vaccine every month and 400 million doses of the Oxford vaccine by the end of 2020, lately obtained $150 million from Bill &amp; Melinda Gates Foundation for its vaccine development and distribution. GAVI has also announced funding for producing initial shots of this vaccine in the nation, added the record.